

A KARDIOVASCULARIS BETEGSÉGEK EVIDENCIÁKON ALAPULÓ MEGELŐZÉSE

- 1. Alberti KG, Zimmel PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539–553.
- 2. Wood D, de Backer G, Faergeman O, et al. Clinicians manual on total risk management. In: Caverport L, editor. A guide to prevention of coronary heart disease. London: Science Press. 2000.
- 3. National Heart Foundation of Australia. Guide to risk reduction of patients with or 'at risk' of cardiovascular disease. Canberra: NHF. 2000.
- 4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N. Engl J Med* 2000; 342: 145–153.
- 5. National Institutes of Health. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med* 1997; 157: 2413–2446.
- 6. Swedberg K, Held P, Kjeksus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med* 1992; 327: 678–684.
- 7. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardia: Evaluation (TRACE) Study Group. *N. Engl J Med* 1995; 333: 1670–1676.
- 8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993; 342: 821–828.
- 9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N. Engl J Med* 1992; 327: 669–677.
- 10. Swedberg K, Sharpe N. The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction. *Eur Heart J* 1996; 17: 1306–1311.
- 11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; 288: 2981–2997.
- 12. The management of hypertension: a consensus statement. *Med J Aust* 1994; 160(6Suppl): S1–S16.
- 13. Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction – evidence from clinical trials. *N. Engl J Med* 1996; 336: 1660–1667.
- 14. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985; 27: 335–371.
- 15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998; 339: 489–497.
- 16. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. *Lancet* 2000; 356: 1949–1964.
- 17. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Lancet* 2000; 356: 1956–1964.
- 18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339: 1349–1367.
- 19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. *N Engl J Med* 1996; 335: 1001–1009.
- 20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383–1389.
- 21. Valterclink JL, Easton JD. Dipyridanole plus aspirin cerebrovascular disease. *Arch Neurol* 1999; 56: 1087–1092.
- 22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. *Lancet* 2002; 360: 7–22.
- 23. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1992; 341: 410–418.
- 24. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. *Lancet* 1997; 349: 1857–1863.
- 25. Marcantori C, Jafar TH, Oldrizzi I, et al. The role of systemic hypertension in the progression of nondiabetic renal disease. *Kidney Int Suppl* 2000; 75: SII–S48.
- 26. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 359: 1033–1041.
- 27. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke gathering the evidence. *Stroke* 1997; 28: 2557–2562.
- 28. Rodgers S, Neal B, McMahon S. The effects of blood pressure lowering in cerebrovascular disease. *Neurol Rev Int* 1997; 2: 12–15.
- 29. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet* 1999; 363: 611–616.
- 30. Tatti P, Pahor M, Byington RP, et al. Cutpoint results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; 21: 597–603.
- 31. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. *Am J Kidney Dis* 2000; 36: 645–661.
- 32. Estazio RO, Jeffers BW, Halt WR, et al. The effect of risoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; 338: 645–662.
- 33. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. *Cochrane Database Syst Ref* 2000; (2): CD002183.
- 34. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; 334: 851–880.
- 35. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The ACE inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. *N Engl J Med* 1996; 334: 939–945.
- 36. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. *Am Intern Med* 1997; 127: 337–345.
- 37. Staessan JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000; 356: 865–872.
- 38. Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy 1998. *Chest* 1998; 114(5 Suppl): 4395–7695.
- 39. American Diabetes Association. Aspirin therapy in diabetes. *Diabetes Care* 2000; 23 (Suppl 1): 861–962.
- 40. Antiplatelet therapy – 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994; 308: 81–105.
- 41. Hansson L, Zanchetti A, Cattruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998; 361: 1756–1762.
- 42. Diener HC, Cunha L, Gorbos C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996; 143: 1–13.
- 43. CAPRI Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRI). *Lancet* 1996; 348: 1329–1339.
- 44. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of the nephrotic syndrome. *Kidney Int* 1985; 28: 429–439.
- 45. Multicentre Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1988; 319: 385–392.
- 46. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial OO – DAVIT II). *Am J Cardiol* 1990; 66: 779–785.
- 47. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. *Prog Cardiovasc Dis* 2000; 43: 171–196.